Skip to content
$2 Off TENA Barrier Cream 150ml with Code: BARRIER2 - Click Here Now!
$2 Off TENA Barrier Cream 150ml with Code: BARRIER2 - Click Here Now!

URGOSTART CONTACT 10X10cm (Piece)

$11.50

Notify me when back in stock

Description

UrgoStart Contact is an innovative non-adhesive, non-occlusive flexible TLC-NOSF* wound contact layer dressing. It is made of a polyester textile mesh coated with the TLC-NOSF* technology.

NICE 2019 medical technology guidance (MTG42) states that evidence supports the case for adopting UrgoStart dressings to treat diabetic foot ulcers and venous leg ulcers.

*Technologie Lipido-Colloïde – Nano-Oligo Saccharide Factor

INDICATIONS :

UrgoStart Contact is indicated for the treatment of chronic wounds (leg ulcers, pressure ulcers, diabetic foot ulcers) and long-standing acute wounds.

BENEFITS:

  • With its unique TLC-NOSF* Healing Matrix (NOSF* impregnated in a TLC healing matrix) UrgoStart is the only local treatment proven to reduce healing time and close wounds sooner
  • The sooner the UrgoStart treatment range is initiated, the more effective it is.
  • The UrgoStart Treatment range’s efficacy in healing significantly sooner has been demonstrated in the highest level of clinical studies (double-blind, randomised controlled trials) and through observational studies.
  • Thanks to the TLC Technology, UrgoStart maintains a moist wound healing environment and allows pain-free & atraumatic removals.

INSTRUCTION for Use :

(References-evidence)

1.Meaume S, et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-Oligo Saccharide Factor wound dressing in the local management of venous leg ulcers. Wound Rep Reg. 2012; 20: 4, 500-511.

2.Edmonds M, Lazaro-Martinez JL, Alfayate-Garcia JM, Martinin J, Petit JM, Rayman G, Lovmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A.  Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial.  Lancet Diabetes Endocrinol. 2018 Mar;6(3)186-196.

3.Meaume S, Truchetet F, Cambazard F et al.  A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers.  Wound Repair Regen. 2012;20:4, 500-511

4.Munter KC, Meaume S, Augustin M, Senet P, Kerijuel JC.  The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings.  J Wound care. 2017 Feb; 26 (sup2): S4-S15.  Erratum in: J Wound Care. 2017 Mar 2; 26(3):153

5.Report to the French minister responsible for Social Security and the French Parliament concerning the evolution of French National Health Insurance charges and products for 2014.  July 2013.